











Interaction between subventricular zone microglia and neural stem cells impacts the neurogenic response in a mouse model of cortical ischemic stroke

Nath *et al.*


Supplementary Information



Supplementary Fig. 1. Cluster identification of the scRNA-Seq dataset. **a**, Hematoxylin and eosin staining of brain sections 7 days after PT. Dotted yellow line delineates lesion core. Scale, 240 μm . Quantification of the infarct volume of mice at day 7 after PT ($n = 3$ mice). **b**, Immunolabeling for CD68 and RFP in the SVZ 1 day after PT. Scale, 36 μm . Quantification of the number of CD68+ cells in the SVZ 1 day after PT ($n = 5$). **c**, Immunolabeling for YFP and DCX in the SVZ of uninjured *Nestin-CreER^{T2}:R26-yfp* mice 12 days after the last tamoxifen injection. Scale, 12 μm . Quantification of the percentage of YFP+DCX+ cells relative to all DCX+ cells ($n = 4$). **d**, Immunolabeling for YFP with Nestin, Sox2, GFAP, Mash1, DCX, NeuN, S100 β , and Olig2 labeling in the SVZ of uninjured *Nestin-CreER^{T2}:R26-yfp* mice. Arrowheads indicate YFP+marker+ and arrows indicate YFP+marker- cells for the marker combinations. Scale, 8 μm . **e**, Quantification of percentage of cell types per total YFP+ cells in the SVZ ($n = 4$). **f**, FACS isolation of SVZ YFP+ NSPCs and CD11b+CD45^{low} microglia. **g**, Immunolabeling for RFP+ blood-derived circulating monocytes (red) in the SVZ at the indicated times after PT and in uninjured *Ccr2-RFP* reporter mice ($n = 5$ mice). Scale, 18 μm . **h**, Immunolabeling for CD45 and RFP in the lesion core (left) and in the SVZ 1 day after PT. Dashed box indicates magnified area showing CD45+ cells in the lesion core (arrowhead). Scales, 180 μm (lesion core), left; 90 μm , magnification; 30 μm , SVZ. Quantification of CD45+ cells in the SVZ in uninjured mice and 1 day after PT ($n = 3$ mice). **i**, UMAP representation of 658 individual NSPCs and microglia from the SVZ 1 and 7 days after PT and uninjured mice measured by scRNA-Seq. Each dot represents an individual cell. All plots show the mean \pm SEM. ns, no significant; *** $P < 0.001$, unpaired Student's *t*-tests (b, h). SVZ, subventricular zone. Source data are provided as a Source Data file.








Supplementary Fig. 2. Quality-control metrics and cluster identification for the scRNA-Seq dataset. **a**, Violin plots depicting number of genes and unique features related to genes, and percentage of transcripts mapping to the mitochondrial genome 1 and 7 days after PT and in the uninjured control. **b**, UMAP plots colored for expression of canonical genes to verify the microglial cluster. **c**, UMAP plots colored for expression of canonical genes to verify the NSPC cluster. **d**, UMAP plots colored for expression of canonical genes to verify the mixed cell population cluster. **e**, Violin plots of mitochondrial genes enriched in different cell populations. **f**, t-SNE plot of microglia cells with the time point of origin, compared with Zywitza's study¹¹.




Supplementary Fig. 3. NSPC activation and apoptosis in the SVZ after cortical stroke.


a, Heat map of the top-10 differentially expressed genes (DEGs) in NSPC clusters. **b**, Quantification of NSPC cluster proportions 1 and 7 days after PT and in uninjured mice. **c**, Immunolabeling for EGFR, GFAP, and Sox2 in uninjured mice and 1 day after PT. The white dashed boxes indicate magnification of EGFR⁻GFAP⁺Sox2⁺ quiescent type B (right, top) and EGFR⁺GFAP⁺Sox2⁺ activated type B cells (star) (right, bottom) in the SVZ in an uninjured mouse and 1 day after PT, respectively. Scales, 25 μ m, left; 12 μ m, magnification. Quantification of EGFR⁺GFAP⁺Sox2⁺ cells in the SVZ per area 1 day after PT and in uninjured mice (n = 6). **d**, Immunolabeling for EdU, GFAP, and Sox2 in the SVZ in uninjured mice and 1 day after PT. Dashed boxes indicate the magnification of an EdU⁻GFAP⁺Sox2⁺ quiescent type B cell (right, top) and an EdU⁺GFAP⁺Sox2⁺ activated type B cell (star) (right, bottom) in uninjured mice and 1 day after PT, respectively. Scale bars, 27 μ m, left; 10 μ m, magnification. **e**, Quantification of EdU⁺GFAP⁺Sox2⁺ (n = 4) and EdU⁺Sox2⁺ (n = 5 mice, uninjured, PT D1; n = 4, PT D3) cells in the SVZ per area 1 day and 3 days after PT and in uninjured mice. **f**, Immunolabeling for Mash1 (green) in the SVZ 7 days after PT, compared with uninjured mice. Scale, 27 μ m. Quantification of Mash1⁺ cells in the SVZ per area 1, 3, 7, and 14 days after PT, and in uninjured mice (n = 6, uninjured; n = 7, PT D1-D14). **g**, *Ascl1*⁺ proliferative type C cells co-express *Mki67*, *Ccdn2*, and *Bcl2*, as in the projected expression of the UMAP after PT. **h**, Quantification of Mash1⁺ApopTag⁺ cell percentage in the SVZ 7 days after PT, compared with uninjured mice (n = 4, uninjured; n = 8, PT D7). All graphs show the mean \pm SEM. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, ns not significant, one-way ANOVAs with Bonferroni corrections for multiple comparisons (e, f) and unpaired Student's *t*-tests (c, h). SVZ, subventricular zone. Source data are provided as a Source Data file.




Supplementary Fig. 4. SVZ microglial molecular heterogeneity after PT. **a**, Heat map of the top-10 DEGs in microglial clusters. **b**, Immunolabeling for Iba1 and RFP in the SVZ (left) and cortex (right) of uninjured *HexB-tdTomato* mice. White boxes indicate magnifications of a RFP+Iba1+ cell (left, top), a RFP+Iba1^{low} cell (left, middle) and a RFP+Iba1- cell (left, bottom) in the SVZ, and a RFP+Iba1+ cell (right, bottom) in the cortex. Examples of each cell type are indicated by arrowheads. Scales, 20 μ m, SVZ; 10 μ m, magnifications of SVZ cells; 35 μ m, cortex; 8 μ m, magnification of the cortical cell. Quantification of the percentage of RFP+Iba1+, RFP+Iba1^{low} and RFP+Iba1- cells in the SVZ and cortex of uninjured mice (n = 4 mice). **c**, Immunolabeling for Iba1 and RFP in the SVZ of uninjured *Cx3cr1-CreER^{T2}:R26-tdTomato* mice. Boxes indicate magnifications of RFP+Iba1+ (right, top), RFP+Iba1^{low} cells (right, middle) and a RFP+Iba1- cell (right, bottom) in the SVZ. Examples of each type of cell are indicated by the white arrowheads. Scales, 33 μ m, SVZ; 9 μ m, magnifications. Quantification of the percentage of RFP+Iba1+, RFP+Iba1^{low}, and RFP+Iba1- cells in the SVZ of uninjured mice and mice 1 day and 7 days after PT (n = 3). **d**, Immunolabeling for CD68, Iba1, and RFP in the SVZ of uninjured *Cx3cr1-CreER^{T2}:R26-tdTomato* mice representing CD68+Iba1-RFP+ (bottom) and CD68-Iba1-RFP+ cells (top). Scale, 12 μ m. Quantification of the CD68 immunoreactivity (IR) in Iba1-RFP+ cells in the SVZ of uninjured mice (n = 3 mice, a total of 21 cells were analyzed). **e**, Immunolabeling for P2ry12 and RFP in the SVZ of uninjured *Cx3cr1-CreER^{T2}:R26-tdTomato* mice and mice 1 and 7 days after PT. Boxes indicate magnification of representative cells showing P2ry12 expression at 1 and 7 days after PT and in uninjured mice (n = 3). Scales, 25 μ m; 8 μ m, magnifications. **f**, Immunolabeling for C1qb and RFP of uninjured *Cx3cr1-CreER^{T2}:R26-tdTomato* mice and mice 1 and 7 days after PT. Scale, 8 μ m. Quantification of the percentage of C1qb⁺ cells of uninjured mice and mice 1 and 7 days after PT (n = 6, uninjured; n = 4, PT D1, PT D7). All graphs show the mean \pm SEM. ****P<0.0001, ns not significant, one-way ANOVAs with Bonferroni corrections for multiple comparisons. SVZ, subventricular zone. Source data are provided as a Source Data file.



Supplementary Fig. 5. Activated SVZ microglia phagocytose dying neuroblasts after PT. **a**, IMARIS-based automatic quantification of cell morphology of GFP+ microglia 1, 3, and 7 days after PT (n = 6, uninjured, PT D1, PT D3; n = 5, PT D7). **b**, Time-lapse imaging montages revealed phagocytosis of tdT+ NSPCs by GFP+ microglia in the SVZ of *Nestin-CreERT²-R26-tdTomato:Cx3cr1-EGFP* mice. Magnification of regions indicated shows phagocytosis of an NSPC by a microglial cell (bottom insets). Scale, 10 μ m. Quantification of velocity dynamics of microglia and phagocytosis events 7 days after PT compared with uninjured control in SVZ acute slices (velocity: n = 2 (35 cells), uninjured; n = 3 (62 cells), 7 days after PT; phagocytosis events: n = 2, uninjured (5 slices); n = 3, 7 days after PT (5 slices)). **c**, Analysis of NSPC RNA in microglia. Violin plots for the type C cell and neuroblast genes *Ascl1* and *Dcx* in SVZ microglia. **d**, Immunolabeling for RFP and TUNEL dying cells 7 days after PT. Dashed boxes indicate 3-D IMARIS reconstruction of the spatial localization of TUNEL+ dying cell fragments revealing microglia phagocytosis of dying cells (right, arrowheads) (n = 3). Scales, 30 μ m, left; 5 μ m, magnifications. **e**, Immunolabeling for EdU and RFP in the SVZ 1, 3, and 7 days after PT and uninjured mice. Dashed boxes indicate magnification of an EdU-RFP+ microglial cell (right, top, arrowhead) and an EdU+RFP+ proliferating microglial cell (right, bottom, arrowhead) in the SVZ in uninjured mice and 3 days after PT, respectively. Scales, 48 μ m, left; 14 μ m, magnifications. Quantification of RFP+ and EdU+RFP+ cells in the SVZ 1, 3, and 7 days after PT compared to uninjured mice (n = 3). **f**, Immunolabeling for ApopTag and RFP in the SVZ 3 days after PT and uninjured mice. Dashed boxes indicate magnification of ApopTag-RFP+ microglia (arrowheads). An ApopTag+ cell is indicated by an arrow. Scales, 24 μ m, left; 12 μ m, magnifications. Quantification of the percentage of ApopTag+RFP+ cells in the SVZ 1, 3, and 7 days after PT, compared with uninjured mice (n = 3 mice). **g**, Immunolabeling for RFP in the choroid plexus 1, 3, and 7 days after PT, compared with uninjured mice. Scale, 80 μ m. Quantification of RFP+ cells in the choroid plexus in uninjured mice and at different times after PT (n = 3). All graphs show the mean \pm SEM. **P<0.01, ****P<0.0001, ns, not significant, one-way ANOVAs with Bonferroni corrections for multiple comparisons (a, e-g), Mann-Whitney test (b). SVZ, subventricular zone. Source data are provided as a Source Data file.



Supplementary Fig. 6. Depletion of SVZ microglia increases the newborn neuroblast cell number after PT. **a**, Immunolabeling for CD68 and Iba1 in the SVZ of fibrinogen-depleted mice and control mice 10 days after PT. Arrowheads indicate CD68+Iba1+ cells. Scale, 16 μ m. Quantification of CD68+Iba1+ cells in the SVZ of fibrinogen-depleted mice and control mice 10 days after PT ($n = 8$, control; $n = 7$, anicrod). **b**, Immunolabeling for DCX (red) in the SVZ of PLX5622-fed or control uninjured mice. Scale, 13 μ m. Quantification of DCX+ cells in the SVZ in PLX5622-fed or control uninjured mice ($n = 2$). **c**, Immunolabeling for EdU and DCX in the SVZ of PLX5622-fed or control mice 7 days after PT. Arrowheads indicate EdU+DCX+ cells. Scale bar, 19 μ m. Quantification of EdU+DCX+ cells in the SVZ in PLX5622-fed and control mice 7 days after PT ($n = 5$ mice, control; $n = 4$ mice, PLX5622). **d**, Hematoxylin and eosin staining of the brain cortex 7 days after PT in PLX5622-treated and control mice. Area delineated by dotted line corresponds to lesion core. Scale, 500 μ m. Quantification of infarct volume ($n = 3$). **e**, Immunolabeling for GFAP in the cortex 7 days after PT in PLX5622-treated and control mice. Area delineated by the dotted yellow line corresponds to the lesion core. Scale bar, 600 μ m. Quantification of GFAP-immunoreactivity in the glial border ($n = 4$, control; $n = 5$, PLX5622). **f**, Quantification of RFP+ microglia and ApopTag+ cells in the SVZ in PLX5622-fed mice 7 days after PT, compared with control group 7 days after PT ($n = 7$ mice for microglial quantification (left graph); $n = 6$, control; $n = 8$, PLX5622 for ApopTag quantification (right graph)). All graphs show the mean \pm SEM. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, ns, not significant, Mann-Whitney test (d-e), and unpaired Student's t -tests (a, c, f). SVZ, subventricular zone. Source data are provided as a Source Data file.



Supplementary Fig. 7. Lrp8 and ApoE expression in SVZ NSPCs and microglia after PT. **a**, Representative immunolabeling image showing Lrp8 (green) and Sox2 (red) in the SVZ 7 days after PT ($n = 4$ mice). Scale bar, 10 μm . **b**, *In situ* hybridization for *Lrp8* (red) and *ApoE* (green) 7 days after PT, compared with uninjured mice. White dashed boxes indicate the magnification of an *Lrp8*⁺ cell next to a *ApoE*⁺ cell (yellow asterisk) in the SVZ 7 days after PT, compared with *Lrp8*⁻ and *ApoE*⁻ cells in the SVZ of uninjured mice ($n = 2$ mice, uninjured; $n = 4$ mice, PT D7). Scale bars, 27 μm , left; 7 μm , right. **c**, Immunolabeling for Lrp8 (green) and DCX (red) in the SVZ in fibrinogen-depleted mice compared with control-treated mice 6 days after PT. Scale bar, 20 μm . Quantification of the percentage of Lrp8+DCX+ cells in fibrinogen-depleted mice compared with control-treated mice 6 days after PT ($n = 7$ mice). The plot shows the mean \pm SEM. ns = not significant, unpaired Student's *t*-tests. SVZ, subventricular zone. Source data are provided as a Source Data file.